In this trial of 3846 patients with class 2-4 systolic CHF (EF <40%) who were intolerant of ACE inhibitors, they were randomized to 50mg or 150mg of losartan. Those in the high dose group had a lower risk of death/CHF hospitalization than the low dose group, at a median of 4.7 years (43% vs 46%). Increasing the losartan dose of CHF patients produces a small but signficant reduction in CHF admission/deaths (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.